Quarterly report pursuant to Section 13 or 15(d)

CONVERTIBLE LOANS (Narrative) (Details)

v3.19.1
CONVERTIBLE LOANS (Narrative) (Details) - USD ($)
1 Months Ended 3 Months Ended 4 Months Ended
May 31, 2019
May 07, 2019
Dec. 31, 2018
Mar. 31, 2019
Feb. 28, 2018
Mar. 31, 2019
Proceeds from issuance of convertible loans $ 5,000,000 $ 500,000 $ 250,000 $ 0 $ 720,000 $ 250,000
Offshore investors [Member]            
Proceeds from issuance of convertible loans           $ 250,000
Debt Instrument, Interest Rate, Stated Percentage       2.00%   2.00%
Incremental Common Shares Attributable to Conversion of Debt Securities           35,714
Incremental Warrants Attributable to Conversion of Debt Securities           35,714
Incremental Warrants Attributable to Conversion of Debt Securities, exercise price           $ 7
Hemogenyx-Cell [Member]            
Pre-money valuation       $ 12,000,000   12,000,000
Immugenyx, LLC [Member]            
Pre-money valuation       $ 8,000,000   $ 8,000,000